RNA
Atrium TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The constructive case is that Atrium launched with about $270 million in cash, a stated runway through clinical proof-of-concept, two lead cardiomyopathy assets, and ongoing collaboration optionality including up to $1.5 billion of potential R&D milestones from existing BMS and Lilly collaborations [#PR-2026-02-27] [#IR-2026-02].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.1.
What can break
Collaboration economics are milestone-based and contingent; the April payment is positive, but future BMS or Lilly value realization is not assured [#PR-2026-04-23] [#IR-2026-02].
Momentum
28
Value
57
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $12.00 · Bull $20.00 · Bear $7.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-07 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $74.90
Why
Momentum28 · Δ7d +11.1
Value57 · Δ7d +0.1
Sentiment51 · Δ7d +6.7
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
28
34% active weight
Current posture
7d trendImproving
Δ7d
+11.1
Δ21d
+16.5
Value
57
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.3
Sentiment
51
33% active weight
Current posture
7d trendImproving
Δ7d
+6.7
Δ21d
+11.9
Why this grade
Composite grade D. Momentum 28.3 / Value 56.7 / Sentiment 50.9
Fundamentals (TTM)As of 2026-05-29
Fundamentals (TTM)
As of 2026-05-29
Market Cap
$222.37M
Beta
0.93
Shares Out
150.68M
P/E (TTM) · Derived
-0.5
P/S (TTM)
520.38
P/FCF (TTM) · Derived
-0.33
Rev YoY
+434.0%
EPS YoY
-94.1%
Gross Margin
-
Op Margin
-2934.9%
Net Debt
-$1.5B
Current Ratio
11.57
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology